Explore the latest in pharmocogenetics, including advances in personalized medicine from genetic markers of drug efficacy and adverse effects.
This Viewpoint discusses issues associated with the use of pharmacogenetic tests to guide treatment in patients with major depressive disorder.
This study investigates anaplastic lymphoma kinase rearrangements in a large series of peritoneal mesothelioma tumors.
This randomized clinical trial compares clinically guided vs genotype-guided dosing to assess whether it improves the safety of warfarin initiation in patients undergoing elective hip or knee arthroplasty.
This narrative review summarizes the current state of genomic testing for somatic mutations in breast cancer and considers approaches for more effective implementation.
This cohort study examines whether selective serotonin reuptake inhibitor exposure during pregnancy is associated with speech/language, scholastic, and motor disorders in offspring up to early adolescence.
This meta-analysis compares patient outcomes in phase 1 trials that used a biomarker selection strategy with those that did not.
This Medical News article discusses barriers to widespread implementation of genotype-guided prescribing.
This meta-analysis of genetic association studies summarizes associations between molecular targets of lipid-lowering therapy and risk of type 2 diabetes and coronary artery disease.
This Viewpoint summarizes recent advances in the management of metastatic castration-resistant prostate cancer.
This secondary analysis of the PETACC-8 clinical trial analyzes the effect of DPYD variants on fluorouracil-related adverse events in patients with stage III colon cancer treated with a fluorouracil, leucovorin, and oxaliplatin regimen.
This randomized placebo-controlled trial of patients with premalignant lesions validated loss of heterozygosity as a marker of oral cancer risk, associated with increased EGFR copy number; however, treatment with erlotinib, an EGFR inhibitor, did not improve cancer-free survival in high-risk patients.
This phase II cohort study examined the cardiac safety of paclitaxel and trastuzumab in patients with node-negative, ERBB2-positive breast cancer and found that the cardiac toxic effects were low, suggesting that left ventricular ejection fraction monitoring could be simplified for many patients.
This Viewpoint highlights the role of next-generation sequencing in the rapid emergence of new cancer therapies as well as the challenges of safely regulating these therapies without unnecessarily delaying their implementation.
Customize your JAMA Network experience by selecting one or more topics from the list below.